Evidence map›Paper›PMID 40167877›Full record

ArticlePharmacological reports : PR2025

Potential drug-drug interactions analysis in Polish pediatric hemato-oncologic unit, including acute lymphoblastic leukemia patients.

Arkadiusz Adamiszak, Julia Drobińska, Izabela Niewiadomska-Wojnałowicz, Katarzyna Derwich, Edmund Grześkowiak, Agnieszka Bienert

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmacological reports : PR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Arkadiusz AdamiszakDepartment of Pharmacology, Poznan University of Medical Sciences, Rokietnicka 3, Poznań, 60-806, Poland. arkadiusz.adamiszak@student.ump.edu.pl.ORCID http://orcid.org/0000-0002-5485-9975
Julia DrobińskaDepartment of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences, Rokietnicka 3, Poznań, 60-806, Poland.ORCID http://orcid.org/0009-0008-6416-7068
Izabela Niewiadomska-WojnałowiczDepartment of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, Szpitalna 27/33, Poznań, 60-572, Poland.ORCID http://orcid.org/0009-0002-7598-3665
Katarzyna DerwichDepartment of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, Szpitalna 27/33, Poznań, 60-572, Poland.ORCID http://orcid.org/0000-0001-7239-4035
Edmund GrześkowiakDepartment of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences, Rokietnicka 3, Poznań, 60-806, Poland.ORCID http://orcid.org/0000-0002-9938-6729
Agnieszka BienertDepartment of Pharmacology, Poznan University of Medical Sciences, Rokietnicka 3, Poznań, 60-806, Poland.ORCID http://orcid.org/0000-0001-7272-5738

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe lack of information on drug-drug interactions in the pediatric population significantly complicates making effective therapeutic decisions. Our study aimed to analyze the rate and risk factors as well as present potential drug-drug interactions (pDDIs) specifically for pediatric patients from the pediatric hemato-oncologic unit, including acute lymphoblastic leukemia (ALL) patients.

methodsWe conducted a six-month prospective study in which clinical pharmacists examined medical records once a week to look for pDDIs using the Lexicomp

resultsWe identified 507 pDDIs in 119 screened patients, 388 of which were clinically relevant. Nearly 68% of the patients were exposed to at least one significant interaction. The number of pDDIs was positively correlated with the number of medications (r

conclusionsLimited data on drug-drug interactions in the pediatric population emphasizes the need for close collaboration between clinical pharmacists and clinicians to improve the safety and effectiveness of pharmacotherapy.

Indexed as

Precursor Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolDrug InteractionsFemaleHumansInfantMalePharmacistsPolandProspective StudiesRisk FactorsAcute lymphoblastic leukemiaClinical pharmacyDrug-drug interactionsPediatric oncologyPediatrics

Identifiers

PMID40167877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.